← All trials
NCT05767632
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 30, 2022
- Primary completion
- Jul 25, 2022
- Completion date
- Oct 25, 2022
- First posted
- Mar 14, 2023
- Last posted
- Mar 14, 2023
- Enrollment
- 30
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Genuine Research Center, EgyptLead sponsor
- HikmaCollaborator
- Genuine Research Center, EgyptStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.